

Disclosures

Personal Commercial (11)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Amgen	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Arrowhead	Consultant Fees/Honoraria	Modest (< \$5,000)	
Avilar Therapeutics	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
CRISPR Therapeutics	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Editas	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Eli Lilly and Company	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Lilly	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Novartis	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Precision Biosciences	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Regeneron	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
UltraGenyx	Consultant Fees/Honoraria	Modest (< \$5,000)	

Additional Personal Commercial Disclosures for Education Activities (9)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Amgen Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Arrowhead	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
CRISPR Therapeutics	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Eli Lilly and Company	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
MediMergent LLC	Stock	Significant (>= \$5,000)	Prevention
Precision BioSciences	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Regeneron	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
UltraGenyx	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Wolters Kluwer	Other - <i>Royalties</i>	Significant (>= \$5,000)	Prevention

Personal Organizational or Other Non-Commercial (1)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
UpToDate, Inc.	Other - <i>Royalties</i>	Significant (>= \$5,000)	Prevention

Clinical Trial Enroller (5)

Trial Name	Trial Sponsor	Trial Funding Source
Fourier Open Label Extension, Metchnikoff, Phase 2 trial with AMG 890	Amgen	
ARO CIII and ARO ANGPTL3	arrowhead	
JF-MC-EZCB 25003	Eli Lilly and Company	
Orion 3, Orion 8, Orion 15, VICTORIAN Plaque, Victorian 2 Prevent	Novartis Corporation	
1628, 1629, 1643, 1522	Regeneron	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/12/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/12/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 10/12/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 10/12/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.